SOD1 and Parkinson disease: By contrast, significant increases (1.9-to-6.8-fold) in eight atypical SOD1 PTMs were identified in the SNc of Parkinson disease patients compared with controls (Fig. 1f, g; Supplementary Table 6), all of which have been shown to induce structural disorder and aggregation of the protein in vitro [55, 61, 89].